Genetic mechanisms that moderate effects of Aβ accumulation in preclinical Alzheimer's disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1111603

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Alzheimer’s disease (AD) is the most common form of dementia, and the number of people living with it will triple by 2050. There is currently no cure for AD, and the only means of slow the growing epidemic is to delay onset. We propose to understand the complex interplay between genetic, cognitive, neuroimaging and biological markers of AD in order to better understand the disease process, and in turn identify high-risk individuals for clinical trials and uncover disease-modifying strategies.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2020

Funding Scheme: Targeted Calls

Funding Amount: $603,525.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Neurology and Neuromuscular Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Alzheimer disease | amyloid | apolipoprotein E | biomarkers | cognition

Related Links